AbbVie to acquire Stemcentrx and with it rovalpituzumab tesirine (Rova-T) treatment for small cell lung cancer

Deciphera Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO), under which ONO will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash through a tender offer followed by a merger of Deciphera with a wholly-owned subsidiary of ONO (the “Acquisition”), for a total equity value of $2.4 billion